---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-018924"
form_type: "8-K"
ticker: "AMIX"
cik: "0001617867"
company_name: "Autonomix Medical, Inc."
filed_at: "2024-05-31T23:59:59+00:00"
generated_at: "2026-06-01T07:10:41.242100+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Autonomix Medical FY2024 net loss $15.4M; cash $8.6M; topline data from first 5 patients expected June

## Summary
- Net loss $15.4M vs $2.0M prior year, including $8.0M non-cash warrant loss; G&A $5.2M, R&D $2.2M.
- Cash $8.6M at March 31, 2024; expects runway into Q1 2025 after $9.8M net IPO proceeds.
- IPO raised $11.2M gross ($9.8M net) via 2,234,222 shares at $5.00 each.
- PoC human clinical study for pancreatic cancer pain ongoing; topline data from first 5 patients expected in June 2024.
- Preclinical study showed statistically significant reduction in metastases and tumor mass with targeted nerve ablation.

## SEC filing metadata
- accession: 0001437749-24-018924
- form_type: 8-K
- ticker: AMIX
- cik: 0001617867
- company_name: Autonomix Medical, Inc.
- filed_at: 2024-05-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1617867/000143774924018924/0001437749-24-018924-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1617867/000143774924018924/amix20240531_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-018924
- JSON: https://secwatch.observer/filing/0001437749-24-018924.json
- Plain text: https://secwatch.observer/filing/0001437749-24-018924.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.